Literature DB >> 15324475

A review of selected anti-tumour therapeutic agents and reasons for multidrug resistance occurrence.

M Sawicka1, M Kalinowska, J Skierski, W Lewandowski.   

Abstract

It is assumed that proteins from the ABC family (i.e., glycoprotein P (Pgp)) and a multidrug resistance associated protein (MRP) play a main role in the occurrence of multidrug resistance (MDR) in tumour cells. Other factors that influence the rise of MDR are mechanisms connected with change in the effectiveness of the glutathione cycle and with decrease in expression of topoisomerases I and II. The aim of this review is to characterize drugs applied in anti-tumour therapy and to describe the present state of knowledge concerning the mechanisms of MDR occurrence, as well as the pharmacological agents applied in reducing this phenomenon.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15324475     DOI： 10.1211/0022357044265

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN： 0022-3573            Impact factor:   3.765


  10 in total

1.  Molecular evidence and functional expression of a novel drug efflux pump (ABCC2) in human corneal epithelium and rabbit cornea and its role in ocular drug efflux.

Authors:  Pradeep K Karla; Dhananjay Pal; Tim Quinn; Ashim K Mitra
Journal:  Int J Pharm       Date:  2006-11-15       Impact factor: 5.875

2.  Molecular expression and functional evidence of a drug efflux pump (BCRP) in human corneal epithelial cells.

Authors:  Pradeep K Karla; Ravinder Earla; Sagar H Boddu; Thomas P Johnston; Dhananjay Pal; Ashim Mitra
Journal:  Curr Eye Res       Date:  2009-01       Impact factor: 2.424

3.  Comparative analysis of CK2 expression and function in tumor cell lines displaying sensitivity vs. resistance to chemical induced apoptosis.

Authors:  Giovanni Di Maira; Francesca Brustolon; Kendra Tosoni; Sara Belli; Stefanie D Krämer; Lorenzo A Pinna; Maria Ruzzene
Journal:  Mol Cell Biochem       Date:  2008-06-17       Impact factor: 3.396

4.  Markers of chemoradiation resistance in patients with locally advanced head and neck squamous cell carcinoma, treated by intra-arterial carboplatin and concurrent radiation.

Authors:  L Mannarini; G Bertino; P Morbini; C Villa; M Benazzo
Journal:  Acta Otorhinolaryngol Ital       Date:  2007-08       Impact factor: 2.124

5.  Block of CFTR-dependent chloride currents by inhibitors of multidrug resistance-associated proteins.

Authors:  Tullia Diena; Raffaella Melani; Emanuela Caci; Nicoletta Pedemonte; Elvira Sondo; Olga Zegarra-Moran; Luis J V Galietta
Journal:  Eur J Pharmacol       Date:  2007-02-03       Impact factor: 4.432

6.  Effects of the CK2 inhibitors CX-4945 and CX-5011 on drug-resistant cells.

Authors:  Sofia Zanin; Christian Borgo; Cristina Girardi; Sean E O'Brien; Yoshihiko Miyata; Lorenzo A Pinna; Arianna Donella-Deana; Maria Ruzzene
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

7.  Differential damage and repair of DNA-adducts induced by anti-cancer drug cisplatin across mouse organs.

Authors:  Askar Yimit; Ogun Adebali; Aziz Sancar; Yuchao Jiang
Journal:  Nat Commun       Date:  2019-01-18       Impact factor: 14.919

8.  Inhibiting Metastasis and Improving Chemosensitivity via Chitosan-Coated Selenium Nanoparticles for Brain Cancer Therapy.

Authors:  Paweena Dana; Nuttaporn Pimpha; Angkana Chaipuang; Nutthanit Thumrongsiri; Prattana Tanyapanyachon; Anukul Taweechaipaisankul; Walailuk Chonniyom; Natsorn Watcharadulyarat; Sith Sathornsumetee; Nattika Saengkrit
Journal:  Nanomaterials (Basel)       Date:  2022-07-29       Impact factor: 5.719

Review 9.  mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine.

Authors:  Pankaj Gupta; Zao-zhong Su; Irina V Lebedeva; Devanand Sarkar; Moira Sauane; Luni Emdad; Michael A Bachelor; Steven Grant; David T Curiel; Paul Dent; Paul B Fisher
Journal:  Pharmacol Ther       Date:  2006-02-07       Impact factor: 12.310

Review 10.  Sensitization of Cancer Cells to Radiation and Topoisomerase I Inhibitor Camptothecin Using Inhibitors of PARP and Other Signaling Molecules.

Authors:  Yusuke Matsuno; Mai Hyodo; Haruka Fujimori; Atsuhiro Shimizu; Ken-Ichi Yoshioka
Journal:  Cancers (Basel)       Date:  2018-09-28       Impact factor: 6.639
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.